IXC

5.71%

7.4¢ invex therapeutics ltd

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-168

First 168 Last

Share
Profile

Follow
Halo99

282 Posts.

81

23/11/21

22:49

Post #: 57799663
Share

Originally posted by JabraD: ↑

Im pretty sure the accounts you have mentioned are made up of small retail holders, I know for a fact citicorp nominees consists of IG Markets shareholders which are all small retailers. HSBC seems to be the main culrpit however bare in mind this is from inception of the company. Alot would have unloaded after those first set of phase 2 results and the cap raise.

Although at first I wanted IXC to explore another indication after speaking with Tom I think this is a not a value driver for IXC.
Tom in the Bell Potter Investor Preso mentioned the company CUV. People should research CUV, I have conducted research on it, and like IXC is it a 1 drug company with 1 indication. Like IXC it hovered around 50 -100 mill MC leading up to Phase 3 results and only targeting EMA. It is now a 1.5 bill MC company generating annual profits and paying dividends off ONE drug. Read the forums back in 2014-2016, it literally sounds exactly like us today. Quotes like this is a phase 3 company valued at 50 mill MC lolol.

As quoted by Tom after recent discussions.....
'the only drug company on ASX that has actually registered a drug (not a diagnostic or device) for a disease in the last ten years is Clinuvel that I can think of. Everyone else has pretty much butchered their FDA approval or Phase 3 trial failed. That was (and still is) a one trick pony. If we had 2-3 drugs and 2-3 indications, we’d be burning 5x as much money and I very much doubt it lowers the risk profile of Invex, indeed it materially increases the financial risk.
I worked at Sirtex: one approved device, one disease approved - $2 Billion trade sale. Cochlear – built a massive company from one product, one indication. Clinuvel, as discussed.
Opthea – single drug Phase 3
Paradigm – single drug Phase 3'

Do you know whats funny, the exact same thing thats happening to CUV is happening to IXC, and CUV exploded once it started reporting Phase 3 data.....
$2 to as high as $40.....DYOR

Expand

No arguments on the asymmetric risk reward play here - IXC is now ~13% portfolio weighting for me!

My point of looking at the sell side is try understand why the over-powering flow of selling over the past year. I'm reaching a similar conclusion as you - it's mainly early-stage investors responsible for the selling. For these investors, they already made a sizeable return from IXC and thus were happy to sell. It's not a reflection of IXC's future prospects, which are solid and should see the share price rise in multiples from today's levels.

IXC Price at posting: 63.0¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

FHE

Frontier Energy achieves key milestone for Waroona energy project

BRX

Belararox delineates another porphyry in Argentina at Tambo South

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

EMD

Emyria's Empax Centre chosen for mental health clinical trial

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

STX

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

There are more pages in this discussion • 1 more message in this thread...

First 168 Last

Add IXC (ASX) to my watchlist

(20min delay)
Last 7.4¢		Change 0.004(5.71%)		Mkt cap ! $5.561M

Open	High	Low	Value	Volume
7.1¢	7.5¢	7.1¢	$4.091K	54.95K

Buyers (Bids)

No.	Vol.	Price($)
1	198734	7.0¢

Sellers (Offers)

Price($)	Vol.	No.
7.4¢	29802	1

View Market Depth

No.	Vol.	Price($)
1	198734	0.070
1	10000	0.051
1	200000	0.050
1	60001	0.043
2	510000	0.040

Price($)	Vol.	No.
0.074	29802	1
0.075	37000	1
0.076	53829	2
0.077	7950	1
0.080	30000	2

Last trade - 16.10pm 21/06/2024 (20 minute delay)

IXC (ASX) Chart

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-168

Frontier Energy achieves key milestone for Waroona energy project

Belararox delineates another porphyry in Argentina at Tambo South

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Emyria's Empax Centre chosen for mental health clinical trial

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-168

Top Stories

Frontier Energy achieves key milestone for Waroona energy project

Belararox delineates another porphyry in Argentina at Tambo South

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Emyria's Empax Centre chosen for mental health clinical trial

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News